Adstiladrin® (nadofaragene firadenovec-vncg) – New drug approval
December 16, 2022 - The FDA announced the approval of Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg), for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
Top